Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E